A5030138461- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Advanced Breast Cancer Therapies
- Pain Management and Opioid Use
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Pain Mechanisms and Treatments
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Esophageal and GI Pathology
- Oral health in cancer treatment
- Gastrointestinal Tumor Research and Treatment
- Lymphoma Diagnosis and Treatment
- Estrogen and related hormone effects
- Chemotherapy-induced cardiotoxicity and mitigation
- Metastasis and carcinoma case studies
- Radiopharmaceutical Chemistry and Applications
McGill University Health Centre
2013-2023
Royal Victoria Hospital
1987-2022
Royal Victoria Regional Health Centre
2022
Montreal General Hospital
1994-2021
NRG Oncology
2021
Magee-Womens Hospital
2019
Institut Gustave Roussy
2019
University College London
2019
Institute of Cancer Research
2019
Belfast Health and Social Care Trust
2019
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of palbociclib plus letrozole as neoadjuvant PATIENTS AND METHODS Postmenopausal women ER-positive primary BC and tumors greater than or equal 2.0 cm were randomly assigned 3:2:2:2 (2.5 mg/d) for 14 weeks (A); 2 weeks, then (B); (C); weeks. Palbociclib 125 mg/d was administered orally...
One hundred thirteen evaluable patients with previously untreated stage III breast carcinoma were treated three monthly cycles of cyclophosphamide (CYC), doxorubicin (DOX), 5-fluorouracil (5-FU), vincristine (VCR), and prednisone (PRED) (CAFVP). Subsequently, 91 (81%) deemed operable. Patients then randomized to receive surgery or radiotherapy (RT) determine which these modalities afforded better local tumor control. All also received 2 additional years CAFVP in a further attempt eradicate...
Chemotherapy-induced diarrhea (cid) is a common side effect of cancer treatment and can cause significant morbidity mortality. Diarrhea frequently severe enough to require dose reduction of, delay in, or discontinuation chemotherapy. Diarrhea-associated mortality has been reported be as high 3.5% in clinical trials irinotecan bolus 5-fluorouracil colorectal cancer. The frequency cid its impact on patient management are under-recognized practice. A Canadian working group, consisting medical...
•CONTROL trial investigated antidiarrheal strategies including dose escalation in neratinib-treated patients with early HER2+ breast cancer.•Preemptive prophylaxis and reduced the rate, severity, duration of grade 3 diarrhea compared ExteNET.•Lower diarrhea-related discontinuations reductions multiple cohorts ExteNET suggested improved tolerability.•Neratinib is a particularly promising strategy as it eliminates mandatory related side-effects. BackgroundNeratinib an irreversible pan-HER...
PURPOSE: Paclitaxel is an active drug for the treatment of breast cancer; however, appropriate duration administration unknown. We assessed and compared response rate, event-free survival, toxicity paclitaxel 250 mg/m 2 delivered every 3 weeks as a 3-hour or 24-hour infusion. PATIENTS AND METHODS: A total 563 women with stage IV IIIB cancer were randomized into one two groups: 279 received 284 paclitaxel. Patients stratified by age, disease, prior therapy. RESULTS: significantly higher rate...
An improved treatment method for hepatic malignancies with yttrium-90 incorporated into the matrix of glass microspheres was evaluated prospectively. Fifteen patients 12 metastatic colorectal cancers, one carcinoid, islet cell tumor, and hepatoma were treated three dose levels: 5,000 cGy (5,000 rad), ten patients; 7,500 (7,500 10,000 (10,000 two patients. Mean follow-up 7 months (range, 2-12 months). Stable disease in liver seen patients, four whom had concurrent progression extrahepatic...
Twenty-three adult patients with chronic pain due to cancer completed a double-blind, randomized, two-phase crossover trial comparing plasma morphine concentrations and analgesic efficacy of oral sulfate solution (MSS) controlled-release tablets (MS Contin [MSC], Purdue Frederick, Inc., Toronto, Ontario, Canada). MS was given every 12 hours all except those whose daily dose could not be equally divided into two 12-hour doses the tablet strengths available. MSS 4 hours. Patients received both...
Abstract Background The humanized monoclonal antibody (mAb) trastuzumab (H) + chemotherapy (chemo) prolongs disease-free survival (DFS) in patients (pts) with HER2-positive breast cancer (BC) the adjuvant setting. Vascular endothelial growth factor (VEGF-A), one central regulator of angiogenesis, is a downstream target HER2. Tumors overexpressing HER2 also overexpress VEGF-A and exhibit increased angiogenic potential. Combining H anti-VEGF-A mAb bevacizumab (B) significantly decreased tumor...
The short elimination half-life of hydromorphone necessitates 4-hourly dosing to maintain optimal levels analgesia in patients with chronic cancer pain. purpose this study was compare the clinical efficacy and safety controlled release administered every 12 hours immediate 4 severe pain.Forty-eight stable pain were randomized, a double-masked crossover study, or for 7 days each. Pain intensity assessed using visual analog scale (VAS) Present Intensity Index McGill Questionnaire. Nausea...
PURPOSE Human epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies heavily pretreated HER2+/HER2-low cancer. METHODS In...
Although the pharmacokinetics of oral hydromorphone has been evaluated in healthy volunteers after small single doses, data are not available regarding disposition and its principal metabolite, hydromorphone‐3‐glucuronide (H3G), at steady‐state large doses. The authors studied H3G administration an immediate‐release (IR) controlled‐release (CR) formulation a daily dose 48 ± 11 mg (range 6–216 mg) randomized, double‐blind, steady‐state, two‐way crossover evaluation 18 patients with chronic...
Capecitabine, an oral prodrug of 5-fluorouracil (5FU), has been integrated into the management multiple cancer types because convenience administration and efficacy comparable with 5fu. Cardiotoxicity induced by 5FU-in particular angina-has well described in literature, but reports adverse cardiac events capecitabine are also emerging. The mechanism underlying 5FU cardiotoxicity long thought to result from coronary vasospasm, animal-model studies patient echocardiographic findings both...
Patients with breast cancer and brain metastases (BM) have a poor prognosis high clinical need for novel treatments; however, historically, studies often excluded these patients. Although the BEACON study did not meet its primary end point, treatment etirinotecan pegol vs chemotherapy of physician's choice patients advanced demonstrated significant improvement in overall survival (OS) prespecified patient subgroup preexisting, pretreated, nonprogressive BM.
In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement overall survival has considered "gold standard"-the most convincing measure efficacy. However, requires larger patient numbers and longer follow-up may often be confounded by other factors, including subsequent therapies crossover. Given number active for potential investigation, demand rapid evaluation early availability new is growing. Progression-free...
Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea the most frequent side effect common reason early discontinuation. The phase II CONTROL trial investigated antidiarrheal prophylaxis or neratinib dose escalation (DE) prevention of diarrhea. We present complete study results including final data two DE strategies.Patients who completed trastuzumab-based adjuvant therapy received 240 mg/day 1 year. Early...
PURPOSE: To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that 5-FU/leucovorin (LV) as first-line therapy for patients metastatic/advanced colorectal cancer. PATIENTS AND METHODS: This multicenter, randomized, open-label, phase III study (FUMA3008) conducted in United States Canada compared safety EU/5-FU (11.5 mg/m 2 /1.15 twice daily 28 days every 35 days) intravenous 5-FU/LV (425 /20 once 5 previously untreated metastatic Overall survival (OS) was...